Irbesartán Davur (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal glands. By preventing angiotensin II from binding, it reduces vasoconstriction and aldosterone secretion, leading to lower peripheral resistance, decreased blood volume, and a reduction in arterial blood pressure.

The appropriate dose of Irbesartán Davur is determined by the prescribing clinician based on the individual’s blood pressure, kidney function, and overall health status. Dosage adjustments may be required during therapy, and patients should follow the prescriber’s instructions exactly.

The safety of irbesartan in pregnancy and lactation has not been established, and it is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider.

To order Irbesartán Davur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which unlike ACE inhibitors does not typically cause a dry cough. Compared with calcium‑channel blockers, ARBs specifically target the renin‑angiotensin system, offering renal protective benefits in diabetic patients while having a low incidence of metabolic side effects.

Irbesartán Davur should be stored at temperatures below 25 °C in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Irbesartán Davur is taken orally, usually once daily with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include angioedema, which can cause swelling of the face or throat, acute renal failure indicated by a sudden rise in creatinine, and significant elevations in liver enzymes. Any signs of severe allergic reaction or rapid kidney function decline require immediate medical attention.

Irbesartán Davur should be avoided in patients with known hypersensitivity to irbesartan or any component of the formulation, in those with severe hepatic impairment, and in individuals taking aliskiren who have diabetes. Caution is also advised for patients with existing hyperkalemia or severe renal dysfunction.